Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): Retroviruses and hepadnaviruses

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 2, 2008, Pages 75-105

  De Clercq, Erik ^a   Field, Hugh J ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 3' FLUOROTHYMIDINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR; ADEFOVIR DIPIVOXIL; AMDOXOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; APLAVIROC; APRICITABINE; ATAZANAVIR; BCH 10618; BEVIRIMAT; CALANOLIDE A; CAPRAVIRINE; CLEVUDINE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; ELVUCITABINE; EMIVIRINE; GS 393; L 743; PLERIXAFOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; S 353; UNINDEXED DRUG; VIDEC EC;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HEPADNAVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROVIRUS; RETROVIRUS INFECTION; RISK REDUCTION; STEM CELL MOBILIZATION;

EID: 50349088218     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020801900205     Document Type: Article

References (163)

1. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30:115-133.
2. Daluge SM, Good SS, Faletto MB, et al. 1592U89 succinate - a potent, selective anti-HW carboxylic nucleoside. Antiviral Res 1995; 26:A228.
3. Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12:F117-F122.
4. Vandevelde M, Witvrouw M, Schmit JC, Sprecher S, De Clercq E, Tassignon JP. ADA, a potential anti-HW drug. AIDS Res Hum Retroviruses 1996; 12:567-568.
5. Rice WG, Turpin JA, Huang M, et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med 1997; 3:341-345.
6. Goebel FD, Hemmer R, Schmit JC, et al. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS 2001; 15:33-45.
7. Arends S, Vanhalteren E, Kamp W, Schokker J. Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection - a pilot study. Pharm World Sci 1996; 18:30-34.
8. Pauwels R, Balzarini J, Schols D, et al. Phosphonylmethoxyethyl purine derivatives, a new class of antihuman immunodeficiency virus agents. Antimicrob Agents Chemother 1988; 32:1025-1030.
9. Naesens L, Balzarini J, Bischofberger N, De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis (pivaloyloxymethyl)-9-(2-phosphonylmethoxethyl) adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob Agents Chemother 1996; 40:22-28.
10. Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993; 21:141-153.
11. Langen P, Etzold G, Hintsche R, Kowollik K. 3′-Deoxy-3′-fluorothymidine, a new inhibitor of DNA synthesis. Acta Biol Med Ger 1969; 23:759-766.
12. Kim EY, Vrang L, Öberg B, Merigan TC. Anti-HIV type 1 activity of 3′ fluoro-3′-deoxythymidine for several different multidrug resitant mutants. AIDS Res Hum Retroviruses 2001; 17:401-407.
13. Katlama C, Ghosn J, Tubiana R, et al. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study. AIDS 2004; 18:1299-1304.
14. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus type 1 by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38:668-674.
15. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat Med 1998; 4:72-77.
16. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2:581-587.
17. Kim EE, Baker CT, Dwyer MD, et al. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally Bioavailable inhibitor of the enzyme. J Am Chem Soc 1995; 117:1181-1182.
18. Adkins JC, Faulds D. Amprenavir. Drugs 1998; 55:837-842.
19. Pham PA, Hendrix CW, Barditch-Crovo P, et al. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antivir Ther 2007; 12:963-969.
20. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007; 21:1431-1439.
21. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005; 67:1268-1282.
22. Westby M, van der Ryst. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005; 16:339-354.
23. Ryan CT. Trials of aplaviroc halted in treatment-naïve patients. AIDS Clin Care 2005; 17:107-108.
24. Gu Z, Allard B, de Muys JM, et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:625-631.
25. Wainberg MA, Cahn P, Bethell R, Sawyer J, Cox S. Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. Antivir Chem Chemother 2007; 18:61-70.
26. Cahn P, Altclas J, Martins M, Losso M, Cassetti I, Cooper D. (2007). Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1- infected patients failing therapy with M184V and NRTI resistance. 4th International AIDS Society Conference, 22-25 July 2007, Sydney, Australia. Abstract WESS203
27. De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs 2005; 10:241-274.
28. De Clercq E. A guided tour through the antiviral drug field. Future Virology 2006; 1:19-35.
29. Vergani B, Cicero ML, Vigano O, et al. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving atazanavir. J Clin Virol 2008:154-159.
30. Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003; 100:13555-13560.
31. Adamson CS, Ablan SD, Boeras I, et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006; 80:10957-10971.
32. Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet 2007; 46:589-598.
33. Lin P-F, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A 2003; 100:11013-11018.
34. Ho H-T, Fan L. Nowicka-Sans B, et al. Envelope conformational changes induced by HIV-1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol 2006; 80:4017-4025.
35. Currens MJ, Gulakowski RJ, Mariner JM, et al. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 1996; 279:645-651.
36. Ruckle J, Giltner J, Creagh T, Dutta B, Tolbert D, Xu Z-Q. Clinical safety and pharmacokinetics of (+)-calanolide A. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, 31 January-4 February 1999. Abstract 606.
37. De Clercq E. New anti-HIV agents in preclinical or clinical development. Frontiers in Medicinal Chemistry 2004; 1:543-579.
38. Fujiwara T, Sato A, El-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42:1340-1345.
39. Chu CK, Ma TW, Shanmuganathan K, et al. Use of 2′-Fluoro-5-methyl-beta-L-arabinofurano-syluridine(1-FMAU) as a novel antiviral agent for hepatitis B and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39:979-981.
40. Yoo BC, Kim JH, Chung YH, et al. Twenty-four week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45:1172-1178.
41. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40:140-148.
42. Thompson MA, Kessler HA, Eron JJ, et al. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 2005; 19:1607-1615.
43. Margolis DM, Mukherjee AL, Fletcher CV, et al. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 2007; 21:2025-2032.
44. Gripshover BM, Ribaudo H, Santana J, et al. A5118 Team. Amdoxovir vs placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy. Antivir Ther 2006; 11:619-623.
45. De Meyer S, Azijn H, Surleraux D, et al. TMC114, anovel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
46. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21:1449-1455.
47. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43:761-770.
48. Noser JA, Towers GJ, Sakuma R, Dumont JM, Collins MK, Ikeda Y. Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol 2006; 80:7769-7774.
49. Flisiak R, Dumont JM, Crabbé R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007; 16:1345-1354.
50. Dueweke TJ, Poppe SM, Romero DL, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37:1127-1131.
51. Bellman PC. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998; 12:1333-1340.
52. Geleziunas R, Gallagher K, Zhang H, et al. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′- dideoxy-2′,3′- didehydro-5-fluorocytidine (Reverset™). Antivir Chem Chemother 2003; 14:49-59.
53. Hernandez-Santiago BI, Matthews JS, Rapp KL, Grier JP, Schinazi RF. Antiviral and cellular metabolism interactions between dexelvucitabine and lamivudine. Antimicrob Agents Chemother 2007; 51:2130-2135.
54. Stuyver LJ, Schürmann D, Kravec I, et al. Potent antiviral effect of Reverset in HIV-1 infected adults following a single oral dose. Antivir Ther 2004; 9:529-536.
55. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication competence and drug resistance. J Clin Invest 2001; 107:449-455.
56. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci U S A 1986; 83:1911-1915.
57. Gazzard BG, Moyle GJ. The role of didanosine in the management of HIV-1 infection. Antivir Ther 1997; 2:135-147.
58. Young SD, Britcher SF, Tran LO, et al. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type i reverse transcriptase. Antimicrob Agents Chemother 1995; 39:2602-2605.
59. De Clercq E. From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future Virology 2006; 1:709-715.
60. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 2007; 73:911-922.
61. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43:1-5.
62. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007; 45:274-279.
63. Piras G, Nakade K, Yuasa S, Baba M. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS 1997; 11:469-475.
64. Baba M, Shigeta S, Tanaka H, et al. Highly potent and selective inhibition of HIV-1 replication by 6-phenyluracil derivatives. Antiviral Res 1992; 17:245-264.
65. Baba M, Shigeta S, Yuasa S, et al. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 1994; 38:688-692.
66. Bridges EG, Dutschman GE, Gullen EA, Cheng YC. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem Pharmacol 1996; 51:731-736.
67. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl)] cytosine. Antimicrob Agents Chemother 1992; 36:2686-2692.
68. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307.
69. Venetta T, DiMassimo B, Johnson MR, et al. Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: pharmacokinetics in rodents, monkeys and man. Antiviral Res 1997; 34:A36.
70. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004; 3:215-225.
71. Chang TT, Gish RG, deMan R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
72. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic Hepatitis B. N Engl J Med 2006; 354:1011-1020.
73. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184:1236-1245.
74. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant humanimmunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
75. TMC125-C223 Writing Group, Nadler JP, Berger DS, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-I: primary 24-week analysis. AIDS 2007; 21:F1-F10.
76. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989; 33:1765-1773.
77. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50:396-415.
78. Spruance SL, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006; 55:47-53.
79. Fried MW, Di Bisceglie AM, Straus SE, Savarese B, Beames MP, Hoofnagle JH. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 1992; 16:127a.
80. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), and investigational nucleosed analgue for chronic hepatitis B. N Engl J Med 1995; 333:1099-1105.
81. Baker C. Chaturvedi PR, Hale MR, et al. Discovery of VX-175/ GW433908, a novel, water-soluble prodrug of amprenavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 26-29 September 1999, San Francisco, CA, USA. Abstract 916.
82. Furfine ES. Baker C, Boehlert C, et al. Preclinical development of GW433908/VX-175, the water-soluble phosphate prodrug of amprenavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 26-29 September 1999, San Francisco, CA, USA. Abstract 917.
83. Helgstrand E, Eriksson B, Johansson NG, et al. Trisodium phosphonoformate, a new antiviral compound. Science 1978; 201:819-821.
84. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199-226.
85. Romines KR, Freeman GA, Schaller LT, et al. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 2006; 49:727-739.
86. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:36-40.
87. Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998; 55:1551-1556.
88. Kraus GA, Zhang WJ, Carpenter S, Wannemueler Y. The synthesis and evaluation of hypericin analogs. Bioorg Med Chem Lett 1995; 5:2633-2636.
89. Farnet CM, Wang B, Hansen M, et al. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 1998; 42:2245-2253.
90. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A 1994; 91:4096-4100.
91. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
92. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:8495-8499.
93. Nevens F, Thomas HC, De Man RA, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113:1258-1263.
94. Marquez VE, Tseng CK-H, Mitsuya S, et al. Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. J Med Chem 1990; 33:978-985.
95. Flanigan ME, Geiger SP, Ford H, Jr., et al. The human HIV/ peripheral blood lymphocyte (PBL)-SCID mouse. J Immunol 1995; 154:6612-6623.
96. Graul A, Silvestre J, Castañer J. Lodenosine. Drugs Future 1998; 23:1176-1189.
97. Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72:7532-7541,
98. Sham H, Kempf D, Molla A, et al. Design, synthesis and biological properties of ABT-378, a highly potent HIV protease inhibitor. Fourth Conference on Retroviruses and Opportunistic Infections 22-26 January 1997, Washington D.C., USA. Abstract 14.
99. The CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-1421.
100. Pauwels R, Andries K, Debyser Z, et al. Potent and selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:1711-1715.
101. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
102. Westby M, Smith-Burchnell C, Mori J et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
103. Kang MS. Uptake and metabolism of BuCast: a glycoprotein processing inhibitor and a potential anti-HIV drug. Glycobiology 1996; 6:209-216.
104. Taylor DL, Sunkara PS, Liu PS, Kang MS, Bowlin TL, Tyms AS. 6-O-Butanoyl castanospermine (MDL 28 574) inhibits glycoprotein processing and the growth of HIV. AIDS 1991; 5:693-698.
105. Lindstroem S, Sahlberg C, Wallberg H, Kalayanov G, Oden L, Naeslund L, Tricycloalkatrienes as non-nucleoside reverse transcriptase inhibitors. WO/2002/070516. 2002 September 12.
106. Sahlberg C, Zhou X-X. Development of non nucleoside reverse transcriptase inhibitors HIV therapy anti-infective Agents. Anti-Infective Agents in Medicinal Chemistry 2008; 7:101-117.
107. Balzarini J, Baba M, Pauwels R, et al. Potent and selective activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside, 3′-fluoro-2,6-diaminopurine-2′,3′-dideoxyriboside, and 3′-fluoro-2′,3′-dideoxyguanosine against human immunodeficiency virus. Mol Pharmacol 1988; 33:243-249.
108. Zhang H, Öberg B, Harmenberg J, et al. Inhibition of multiple-drug resistant (MDR) HIV-1by 3′-fluro-2′,3′-dideoxyguanosine (FLG). Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2002; 42:H-182.
109. Jacquard AC, Brunelle MN, Pichoud C, et al. In vitro characterization of the anti-HBV acitivity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine. Antimicrob Agents Chemother 2006; 50:955-961.
110. Reich SH, Melnick M, Davies JF, II, et al. Protein structure based design of potent orally available nonpeptide inhibitors of human immunodeficiency virus protease. Proc Natl Acad Sci U S A 1995; 92:3298-3302.
111. Shetty BV, Kosa MB, Khalil DA, Webber S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40:110-114.
112. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 1990; 250:1411-1413.
113. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:1019-1030.
114. Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. Lancet 2007; 370:1668-1670.
115. Vrang L, Agreu C, Ekelof K, et al. Anti-HIV activity of PETT-4 in vitro. Antiviral Res 1998; 37:A55.
116. Zhang H, Öberg B, Böttiger D, et al. MIV-150 in a vaginal microbicide with superior anti-HIV activities. XV International SIDS conference, 12-16 July 2004, Bangkok, Thailand. Abstract TuPeB4667.
117. Fernández-Romero JA, Thorn M, Turville SG, et al. Carrageenan/ MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007; 34:9-14.
118. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987; 31:1238-1242.
119. Spruance SL, Boon R, Saltzman R, Tucker R, Thoming C, Rea TL. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997; 277:1374-1379.
120. Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4:241-246.
121. Roth S, Monsour M, Dowland A, et al. (2007) Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells. Antimicrob Agents Chemother 2007; 51:1972-1978.
122. Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996; 40:234-236
123. Gantlett KE, Weber JN, Sattentau QJ, Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res 2007; 75:188-197.
124. Cahn P, Sosa N, Wiznia A, et al. Racivir demonstrates safety and efficacy in patients harboring HIV with the M184V mutation and less than 3 TAMs. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 25-28 February 2007. Abstract 488.
125. Otto MJ, Arastèh K, Kreckel P, et al. Sustained anti-HIV-1 effect of Racivir combined with D4T and Sustiva following a 14-day treatment of infected volunteers. 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, MA, USA. Abstract 552.
126. Otto MJ, Arasteh K, Schulbin H, et al. Single and multiple dose pharmacokinetics and safety of the nucleoside Racivir in male volunteers. Frontiers in Drug Development for Antiretroviral Therapies, HIV DART 2002, 15-19 December 2002, Naples, FL, USA. Abstract 044.
127. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515.
128. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
129. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4- 4-4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]- 2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48:1901-1909.
130. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 2006; 20:1721-1726.
131. van 't Klooster G, Verloes R, Baert L et al. Long-acting TMC278, a parenteral depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008 Boston, MA, USA. Oral abstract 134.
132. Markowitz M, Hongnei MO, Kemp D, et al. Selection and analysis of human immunodeficiency virus type 1 variant with increased resistance to ABT-538, a novel protease inhibitor. J Virol1995; 69:701-706,
133. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS 1998; 12:1495-1502.
134. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibition. Science 1990; 248:358-361.
135. Perry CM, Noble S. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 1998; 55:461-486.
136. Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987; 142:128-134.
137. Lin TS, Schinazi RF, Prusoff WH. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene( 3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol 1987; 36:2713-2718.
138. Barney S, Guthrie K, Davis D, Newman L, Johnson MR, Lambert DM. A novel hybrid synthetic peptide inhibitor of HIV-1, SIV and HIV-2 fusion and infection in vitro. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 31 January-4 February 1999. Abstract 616.
139. Lambert DM, Zhou J, Medinas R, et al. HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T1249. Antivir Ther 1999; 4 Suppl 1:8.
140. Vere Hodge A. Telbivudine/torcitabine (Idenix.Novartis). Curr Opin Investig Drugs 2003; 5:232-241.
141. Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45:229-235.
142. Balzarini J, Holy A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993; 37:332-338.
143. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270:1197-1199.
144. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42:2380-2384.
145. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569-596.
146. Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 1998; 42:1568-1573.
147. Turner SR, Strohbach JW, Tommasi RA, et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41:3467-3476.
148. Thaisrivongs S, Tomich PK, Watenpaugh KD, et al. Structure based design of HIV protease inhibitors: 4-hydroxy coumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1994; 37:3200-3204.
149. Pauwels R, Andries K, Debyser Z, et al. New [4,5,1-JK] [1,4]benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 and are synergistic with 2′,3′-dideoxynucleoside analogues. Antimicrob Agents Chemother 1994; 38:2863-2870.
150. Zhang H, Vrang L, Backbro K, et al. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives Trovirdine and MSG-127. Antiviral Res 1995; 28:331-342.
151. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future. Chem Biodivers 2004; 1:44-64.
152. Ahgren C, Backro K, Bell FW, et al. The PETT series, a new class of potent non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39:1329-1335.
153. Larsson A, Stenberg K, Ericsson A-C, et al. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs rwelated to buciclovir. Antimicrob Agents Chemother 1986; 30:598-605.
154. Soike KF, Bohm R, Huang J-L, Öberg B. Efficacy of (-)-9[4-Hydroxy-2-(Hydroxymethyl)Butyl] Guanine in African green monkeys infected with simian varicella virus. Antimicrob Agents Chemother 1993; 37:1370-1372.
155. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006; 147:1-11.
156. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536.
157. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49:4911-4919.
158. Schürmann D, Fätkenheuer G. Revnes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299.
159. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-312.
160. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci U S A 1986; 83:1191-1915.
161. Moyle GJ, Gazzard BG. Finding a role for zalcitabine in the HAART era. Antivir Ther 1998; 3:125-137.
162. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985; 82:7096-7100.
163. Ioannidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness - a meta analysis. Ann Intern Med 1995; 122:856-866.